Obesity Medication: Types, How It Works, and Who Qualifies

Obesity medications work through several distinct biological pathways, from blocking fat absorption in the gut to altering appetite signals in the brain, and the field has expanded dramatically in recent years with the arrival of drugs that can produce weight loss once only achievable through surgery. Who qualifies depends on a combination of body mass index and the presence of weight-related health problems, with clinical guidelines generally setting the threshold at a BMI of 30 or a BMI of 27 with at least one condition like high blood pressure or type 2 diabetes. The specifics of how each drug type works, what the evidence shows they can and cannot do, and the practical realities of staying on them are worth understanding in detail.

Who Qualifies

The Endocrine Society’s clinical practice guideline lays out a tiered framework that most prescribers follow. Lifestyle changes, meaning diet, exercise, and behavioral strategies, are recommended for anyone with a BMI of 25 or above. Prescription weight-loss medication becomes an option at a BMI of 30 or higher, or at a BMI of 27 or higher when accompanied by at least one obesity-related condition such as type 2 diabetes, high blood pressure, high cholesterol, or obstructive sleep apnea. Bariatric surgery enters the picture at a BMI of 35 with a comorbidity, or 40 without one.¹

In practice, your doctor is looking at the full picture: how long you’ve been carrying excess weight, whether previous attempts at lifestyle modification have stalled, and which health conditions are already present or developing. The guideline frames medication as an adjunct to behavioral changes, not a replacement. That distinction matters because most clinical trials of obesity drugs enrolled participants who were also following a reduced-calorie diet and getting counseling, so the results reflect medication plus effort, not medication alone.

The Older Toolkit

The earliest prescription weight-loss drugs were amphetamine derivatives, including phentermine and diethylpropion, which suppress appetite by ramping up norepinephrine and dopamine activity in the brain. They were widely used in the 1950s and 1960s, but concerns about cardiovascular risk and addiction led to a steep decline by the early 1970s.² Phentermine is still prescribed today, usually only for short-term use, and it’s also combined with the anticonvulsant topiramate in a formulation that works through multiple neurotransmitter pathways to reduce appetite.³

Orlistat takes a completely different approach. Rather than acting on the brain, it works in the gut by binding to the enzymes that break down dietary fat. At the standard dose taken with meals, it blocks roughly 30% of ingested fat from being absorbed, which translates to an additional calorie deficit of about 200 calories per day.⁴ The unabsorbed fat passes through the digestive system, which is the source of orlistat’s well-known side effects: oily stools, gas, and urgent bowel movements if you eat a high-fat meal. In trials lasting up to two years, orlistat produced more weight loss than dieting alone and helped people maintain what they’d already lost.⁵ A lower-dose version is available over the counter in many countries.

Naltrexone/bupropion combines an opioid-receptor blocker with an antidepressant, targeting both the hypothalamic system that regulates hunger and the brain’s reward circuits that drive food cravings. Bupropion stimulates appetite-suppressing neurons, while naltrexone blocks a feedback loop that would otherwise shut those neurons down, amplifying the effect.⁶ The resulting weight loss is more modest than what the newer injectable drugs achieve, but naltrexone/bupropion remains an oral option for people who can’t or don’t want to use injections.

GLP-1 Receptor Agonists and the New Generation

The medications that have reshaped the obesity treatment landscape are the GLP-1 receptor agonists, including liraglutide and the higher-profile semaglutide. These drugs mimic a gut hormone called GLP-1 that your body normally releases after eating. The hormone works through several channels simultaneously: in the brain, it acts on regions that regulate appetite and satiety, reducing hunger and influencing how rewarding food feels; in the pancreas, it enhances insulin secretion and lowers glucagon release, improving blood sugar control; and in the stomach, it slows gastric emptying, meaning food stays in your stomach longer and you feel full sooner.⁷

That slowing of the stomach has both a therapeutic upside and a clinical downside. It contributes meaningfully to satiety, but it can also lead to nausea, fullness, and in some cases symptoms resembling gastroparesis, especially at higher doses.⁸ This is why all GLP-1 drugs are started at a low dose and gradually increased over weeks or months.

Tirzepatide goes a step further by activating two gut hormone receptors at once: GLP-1 and GIP. In a network meta-analysis comparing weight-loss drugs, tirzepatide at its highest dose ranked at the top across weight loss, blood sugar, cholesterol, and blood pressure outcomes. It had the highest odds of achieving at least 15% weight loss compared with placebo.⁹ Still further down the pipeline, retatrutide activates three receptors: GLP-1, GIP, and glucagon. In clinical trials, it achieved mean weight loss of up to about 24% at 48 weeks in people with obesity and also showed striking improvements in liver fat, blood pressure, and cholesterol.¹⁰

Gastrointestinal Side Effects and Serious Risks

The most common side effects of GLP-1-based medications are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These tend to be dose-dependent and often improve as the body adjusts over several weeks.¹¹ For many people, nausea is mild and temporary. For others, it’s the reason they stop treatment. A comprehensive review confirmed that these GI events are the most frequently reported adverse effects for both GLP-1 and dual GLP-1/GIP drugs, with evidence around more severe events like intestinal obstruction and pancreatic issues being mixed and sometimes conflicting across studies.¹²

Some rarer risks deserve attention. A large study comparing GLP-1 users with people taking naltrexone/bupropion found that GLP-1 use was associated with higher rates of pancreatitis, bowel obstruction, and gastroparesis.¹³ A systematic review and meta-analysis also found that GLP-1 drugs increased the risk of gallstones by roughly 46% compared with placebo, and probably doubled the risk of acid reflux, though the absolute numbers were small: about two extra gallstone cases and four extra reflux cases per 1,000 people treated.¹⁴ The gallstone risk appears to stem from these drugs’ effects on gallbladder motility and bile acid signaling.¹⁵

Cardiovascular Benefits

One of the more striking findings to emerge from recent research is that GLP-1 drugs appear to have genuine cardiovascular benefits, not just as a downstream consequence of weight loss but as a measurable clinical outcome. The SELECT trial enrolled over 17,600 people with obesity and existing cardiovascular disease but without diabetes, and found that semaglutide reduced the rate of major cardiovascular events, including heart attack, stroke, and cardiovascular death, by 20% compared with placebo.¹⁶ That’s a substantial effect, and it was the first trial to demonstrate cardiovascular risk reduction with an obesity medication in people who didn’t have diabetes.

A meta-analysis pooling data from 13 randomized trials with over 30,000 patients found that GLP-1 drugs lowered systolic blood pressure by about 5 mmHg and significantly reduced the risk of heart attack.¹⁷ These cardiovascular findings have shifted how doctors think about GLP-1 drugs: for patients with both obesity and heart disease, the drugs are no longer just about weight loss. They’re actively reducing risk.

Metabolic Effects Beyond the Scale

Weight is the most visible outcome, but GLP-1-based medications affect several metabolic systems that matter for long-term health. Fatty liver disease is one area drawing increasing attention. GLP-1 drugs have shown meaningful impacts on biochemical markers of liver fat and even on fibrosis, the scarring that can lead to serious liver disease.¹⁸ The triple agonist retatrutide showed an 82% reduction in liver fat in trial participants, which is unusually dramatic even for this class.¹⁰

Obstructive sleep apnea is another condition that often coexists with obesity. A systematic review found that in people with type 2 diabetes, GLP-1 drugs significantly reduced the frequency of breathing interruptions during sleep. The evidence was less definitive for people with obesity alone, suggesting more research is needed in that group, but the direction of the effect was promising enough that these drugs may be worth considering as part of a broader treatment approach for patients dealing with both conditions.¹⁹

There’s also growing evidence that GLP-1 drugs influence the brain’s reward pathways. Research suggests they normalize some of the dopamine signaling disruptions linked to overeating, reducing cravings and the “reward pull” of food. This may partly explain why some users report a shift in their relationship with food that goes beyond simply feeling less hungry.²⁰

What Happens When You Stop

This is one of the most important and least pleasant realities of obesity medication: for most people, stopping the drug means regaining a large share of the lost weight. A meta-regression analysis found that at one year after stopping treatment, people had regained about 60% of the weight they lost while on the drug. Beyond that point, the trajectory was projected to plateau at roughly 75% of the weight regained.²¹ The rebound happened regardless of how long someone had been on the medication. Blood sugar, which typically improves during treatment, showed signs of reverting within weeks of stopping, and blood pressure followed a similar pattern, with most of the initial improvement lost within about three months.

A separate meta-analysis comparing people who discontinued GLP-1 drugs with those who continued treatment found a significant difference in body weight, confirming that the rebound is real and clinically meaningful. Interestingly, the degree of rebound appeared to differ between drugs: weight regain after stopping tirzepatide was greater than after stopping semaglutide, which may reflect differences in how strongly each drug suppresses appetite.²² A narrative review of randomized studies reinforced the same pattern: rapid weight regain after stopping, regardless of which drug was used or how long the person had been treated.²³

The implication is that for most people, obesity medication is not a short course you take until you reach a target weight and then stop. It functions more like medication for high blood pressure or cholesterol: the condition it’s managing persists, so the treatment does too. That framing matters because it changes the math on cost, access, and long-term planning.

Why Results Vary So Much

If you’ve seen headlines about 15% or 20% weight loss and wondered whether that’s guaranteed, it isn’t. The numbers in clinical trials are averages, and behind those averages is a wide spread. Some people lose substantially more weight than the mean, others less, and some barely respond at all. A review exploring this variability noted that while GLP-1 drugs produce a mean weight loss in the range of a few kilograms in diabetes populations, real-world experience reveals significant differences between individuals.²⁴ Researchers are actively trying to identify what predicts a strong response. Factors under investigation include starting weight, age, sex, metabolic profile, and how a person’s individual hunger and reward circuits respond to the drug.²⁵

The gap between trial results and real-world outcomes is also driven by practical factors. In clinical trials, participants receive consistent follow-up, dose adjustments, and behavioral support. In the real world, people miss doses, struggle with side effects, face insurance interruptions, or can’t afford the medication long enough to reach the highest dose. A real-world analysis of commercially insured adults without diabetes found that only about a third of people starting a GLP-1 drug were still on it after one year. Semaglutide had the best persistence at about 47% at one year, while liraglutide’s rate was under 20%.²⁶ Real-world effectiveness is smaller than trial efficacy, partly because of these adherence gaps and partly because of access barriers like cost, insurance prior authorizations, and supply shortages.²⁷

Obesity Medications in Adolescents

Semaglutide was approved in the United States for adolescents aged 12 and older with severe obesity in 2022, based on the STEP-Teens trial. In that 68-week trial, teens on semaglutide saw their BMI drop by about 16% on average, compared with a slight increase in the placebo group. Nearly 45% of participants on semaglutide moved into a normal-weight or overweight BMI category, compared with 12% on placebo.²⁸

A broader meta-analysis of 18 randomized trials involving over 1,400 young people found that GLP-1 drugs reduced body weight, BMI, fasting blood sugar, and systolic blood pressure in children and adolescents, with gastrointestinal side effects being the main safety signal, consistent with what’s seen in adults. Rates of suicidal thoughts or behaviors did not differ from placebo.²⁹ A newer trial has extended the evidence even younger, showing that liraglutide reduced BMI in children aged 6 to 11 compared with placebo.³⁰

The concerns specific to younger patients center on growth, bone health, and nutritional adequacy. Rapid weight loss can include loss of muscle and bone density, which is particularly concerning during puberty when the body is still developing. Adequate protein intake and resistance exercise become especially important. Long-term effects on growth trajectories and pubertal development remain uncertain, which is a genuine gap in the current evidence.

Lean Mass Loss and Exercise

One of the more nuanced concerns with obesity medications, particularly the newer injectable drugs, is the proportion of weight lost that comes from lean tissue rather than fat. Studies report a wide range: in some trials, lean mass accounted for 40% to 60% of total weight lost, while others showed lean mass losses of only about 15% or less.³¹ That’s a wide spread, and it likely depends on factors like how much weight was lost, how fast it came off, and whether the person was exercising during treatment.

This is where combining medication with physical activity becomes more than a talking point. Research on calorie restriction, whether achieved through diet, surgery, or medication, consistently shows that resistance training protects lean mass and bone during weight loss, while aerobic exercise improves cardiovascular fitness on top of that. Doing both together during any weight-loss approach produces the best outcomes for body composition and physical function.³² For someone on a GLP-1 drug who is losing weight rapidly, building in strength training isn’t optional if the goal is preserving muscle and bone health.

Oral Formulations on the Horizon

One of the biggest practical barriers to the current generation of GLP-1 drugs is that most require weekly or daily injections. That’s changing. Orforglipron is a small-molecule GLP-1 receptor agonist designed to be taken as a daily pill. Unlike semaglutide’s oral formulation, which is a peptide requiring specific dosing conditions to survive the stomach, orforglipron is a nonpeptide compound, meaning it’s inherently more stable and potentially easier to manufacture and take. It’s being developed to match the efficacy of injectable GLP-1 drugs while improving convenience.³³

If oral options prove similarly effective to injectables in ongoing phase 3 trials, the access picture could shift considerably. People who are reluctant to self-inject, who travel frequently, or who simply prefer a pill would have a genuine alternative. Combined with the triple-agonist drugs in the pipeline, the next few years of obesity pharmacology look likely to produce more options with stronger effects, though the fundamental challenge of long-term adherence and cost will remain regardless of delivery method.